Core Viewpoint - 甘李药业 has signed a technology transfer and supply agreement with Brazil's Fiocruz and local biopharmaceutical company BIOMM, focusing on the production and development of insulin, which is expected to significantly impact the company's performance in 2025 and beyond [2][3]. Group 1: Partnership and Agreements - The agreements include a supply framework worth at least RMB 3 billion (including tax) and cover the transfer of technology related to insulin, raw materials, injection solutions, and syringes for a period of ten years [2]. - The PDP project aims to strengthen Brazil's public health system and ensure a stable supply of essential medicines through local production [2][4]. Group 2: Market Context and Demand - Brazil has faced insulin supply shortages, leading to an urgent tender for over a million insulin products in 2023, which 甘李药业 successfully supplied [3]. - The project is expected to generate a demand for at least 70 million units of insulin annually, with an initial focus on supplying insulin injection solutions to alleviate clinical shortages [3]. Group 3: Company Performance and Recovery - 甘李药业 has been recovering from the impact of national drug procurement policies, with a reported revenue of RMB 2.067 billion in the first half of 2025, a year-on-year increase of 57.18% [5][6]. - The company has successfully entered the national procurement process, with six products selected, and has achieved a market share of nearly 30% in the third-generation insulin market, ranking second in the industry [6]. Group 4: International Expansion - 甘李药业 is actively pursuing international markets, with a reported revenue of RMB 220 million from international sales in the first half of 2023, a 75.08% increase year-on-year [7]. - The company has established a local production facility in Brazil and is also seeking to penetrate the African market with successful local projects [7][8].

胰岛素集采中选产品价格上涨，新一轮集采协议量增加。 本文为IPO早知道原创 作者｜罗宾 微信公众号｜ipozaozhidao 据IPO早知道消息，10月22日，甘李药业（603087.SH）发布2024年三季报，前三季度实现收入 22.45亿元，同比增长17.81%；归母净利润5.07亿元，同比增长90.36%，主要系前三季度营业收 入、交易性金融资产公允价值变动收益较上年同期大幅增长所致。其中，今年第三季度营业收入为 9.30亿元，同比增长37.61%；实现归母净利润2.08亿元，同比增长57.47%。 第三季度，公司国内外收入均实现增长。 报告期内国内收入为6.80亿元，同比增加22.25%，主要 归因于公司制剂产品价格的上涨。 2024年前三季度，公司国内销售收入18.68亿元，同比增长2.39亿元，其中国内制剂销售收入 18.02亿元，同比增2.21亿元。 来源：公司财报 今年第二季度，公司参加了全国药品集采（胰岛素专项接续）的投标工作，所有产品均中选，且中选 产品价格上涨。新一轮胰岛素集采在二、三季度陆续由各省开始执行，且产品价格上涨推动2024年 前三季度公司总收入增加了1.50亿元。 此外， 公 ...